MedTrace Logo

Ologen (OculusGen)-Glaucoma Case Control Trial in India

NCT00448929 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-06-27

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and effectiveness of trabeculectomy with ologen (OculusGen) Biodegradable Collagen Matrix Implant and trabeculectomy without antifibrotic agents.

Conditions

Interventions

DEVICE

OculusGen Biodegradable Collagen Matrix Implant

Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant

Sponsors & Collaborators

  • Pro Top & Mediking Company Limited

    lead INDUSTRY

Principal Investigators

  • Anil Mandal, MD · V. S. T. Glaucoma Services, L. V. Prasad Eye Institute,

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • India

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448929 on ClinicalTrials.gov